Novel design principles enable specific targeting of imaging and therapeutic agents to necrotic domains in breast tumors

Breast Cancer Research

Volumn 12, Issue 3, 2010, Pages

  Goldshaid, Liat ^a   Rubinstein, Efrat ^a   Brandis, Alexander ^a   Segal, Dadi ^a   Leshem, Noa ^a   Brenner, Ori ^a   Kalchenko, Vyacheslav ^a   Eren, Doron ^b,c   Yecheskel, Tamar ^b   Salitra, Yoseph ^b   Salomon, Yoram ^a   Scherz, Avigdor ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b Steba Laboratories Ltd   (Israel)

^c Kiryat Weizmann Science Park   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

3 1 OXO 15 METHOXYCARBONYLMETHYL RHODOBACTERIOCHLORIN 13 1 (2 SULFOETHYL)AMIDE 17 3 C(RGDFK)AMIDE POTASSIUM SALT; 3 1 OXO 15 METHOXYCARBONYLMETHYLRHODOBACTERIOCHLORIN 13 1 (2 SULFOETHYL)AMIDE DIPOTASSIUM SALT; CELL RECEPTOR; HUMAN SERUM ALBUMIN; INTEGRIN RECEPTOR; RADIOPHARMACEUTICAL AGENT; SERUM ALBUMIN; STL 6014; STL 7012; UNCLASSIFIED DRUG; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; BACTERIOCHLOROPHYLL; DIAGNOSTIC AGENT; OLIGOPEPTIDE;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST NECROSIS; CANCER THERAPY; COMPETITIVE INHIBITION; COMPLEX FORMATION; CONJUGATION; COVALENT BOND; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RETENTION; DRUG STRUCTURE; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; IMAGING SYSTEM; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; TUMOR CELL; WHOLE BODY IMAGING; ANIMAL; BREAST TUMOR; CHEMISTRY; DIAGNOSTIC IMAGING; DRUG DESIGN; METABOLISM; NECROSIS; NUDE MOUSE; TISSUE DISTRIBUTION;

ANIMALS; BACTERIOCHLOROPHYLLS; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; DRUG DESIGN; FEMALE; HUMANS; MICE; MICE, NUDE; NECROSIS; OLIGOPEPTIDES; SERUM ALBUMIN; TISSUE DISTRIBUTION;

EID: 78149478716     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2579     Document Type: Article

References (50)

1. Leek RD, Landers RJ, Harris AL, Lewis CE. Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer 1999, 79:991-995. 10.1038/sj.bjc.6690158, 2362675, 10070902.
2. Kato T, Kimura T, Miyakawa R, Tanaka S, Fujii A, Yamamoto K, Kameoka S, Hamano K, Kawakami M, Aiba M. Clinicopathologic study of angiogenesis in Japanese patients with breast cancer. World J Surg 1997, 21:49-56. 10.1007/s002689900192, 8943177.
3. Lee AH, Happerfield LC, Bobrow LG, Millis RR. Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol 1997, 50:669-673. 10.1136/jcp.50.8.669, 500114, 9301551.
4. Tomes L, Emberley E, Niu Y, Troup S, Pastorek J, Strange K, Harris A, Watson PH. Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res Treat 2003, 81:61-69. 10.1023/A:1025476722493, 14531498.
5. Lee SE, Hong SK, Han BK, Yu JH, Han JH, Jeong SJ, Byun SS, Park YH, Choe G. Prognostic significance of tumor necrosis in primary transitional cell carcinoma of upper urinary tract. Jpn J Clin Oncol 2007, 37:49-55. 10.1093/jjco/hyl123, 17204506.
6. Edwards JG, Swinson DE, Jones JL, Muller S, Waller DA, O'Byrne KJ. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 2003, 124:1916-1923. 10.1378/chest.124.5.1916, 14605068.
7. Sengupta S, Lohse CM, Leibovich BC, Frank I, Thompson RH, Webster WS, Zincke H, Blute ML, Cheville JC, Kwon ED. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 2005, 104:511-520. 10.1002/cncr.21206, 15973740.
8. Cutuli B, Cohen-Solal-le Nir C, de Lafontan B, Mignotte H, Fichet V, Fay R, Servent V, Giard S, Charra-Brunaud C, Lemanski C, Auvray H, Jacquot S, Charpentier JC. Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. Int J Radiat Oncol Biol Phys 2002, 53:868-879. 10.1016/S0360-3016(02)02834-1, 12095552.
9. Bussolati G, Bongiovanni M, Cassoni P, Sapino A. Assessment of necrosis and hypoxia in ductal carcinoma in situ of the breast: basis for a new classification. Virchows Arch 2000, 437:360-364. 10.1007/s004280000267, 11097360.
10. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007, 101:937-949. 10.1002/jcb.21187, 17171643.
11. Weinmann M, Belka C, Plasswilm L. Tumour hypoxia: impact on biology, prognosis and treatment of solid malignant tumours. Onkologie 2004, 27:83-90. 10.1159/000075611, 15007254.
12. Lee K, Roth RA, LaPres JJ. Hypoxia, drug therapy and toxicity. Pharmacol Ther 2007, 113:229-246. 10.1016/j.pharmthera.2006.08.001, 17046066.
13. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4:437-447. 10.1038/nrc1367, 15170446.
14. Patterson AV, Ferry DM, Edmunds SJ, Gu Y, Singleton RS, Patel K, Pullen SM, Hicks KO, Syddall SP, Atwell GJ, Yang S, Denny WA, Wilson WR. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 2007, 13:3922-3932. 10.1158/1078-0432.CCR-07-0478, 17606726.
15. Metz S, Daldrup-Unk HE, Richter T, Rath C, Ebert W, Settles M, Rummeny EJ, Link TM, Piert M. Detection and quantification of breast tumor necrosis with MR imaging: value of the necrosis-avid contrast agent Gadophrin-3. Acad Radiol 2003, 10:484-490. 10.1016/S1076-6332(03)80056-9, 12755535.
16. Kamel IR, Bluemke DA, Ramsey D, Abusedera M, Torbenson M, Eng J, Szarf G, Geschwind JF. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 2003, 181:708-710.
17. Kennan RP, Scanley BE, Gore JC. Physiologic basis for BOLD MR signal changes due to hypoxia/hyperoxia: separation of blood volume and magnetic susceptibility effects. Magn Reson Med 1997, 37:953-956. 10.1002/mrm.1910370621, 9178248.
18. Lang P, Wendland MF, Saeed M, Gindele A, Rosenau W, Mathur A, Gooding CA, Genant HK. Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging. Radiology 1998, 206:227-235.
19. Lehtio K, Eskola O, Viljanen T, Oikonen V, Gronroos T, Sillanmaki L, Grenman R, Minn H. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004, 59:971-982. 10.1016/j.ijrobp.2003.12.014, 15234030.
20. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583-592. 10.1038/nrc1893, 16862189.
21. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006, 11:812-818. 10.1016/j.drudis.2006.07.005, 16935749.
22. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009, 71:409-419. 10.1016/j.ejpb.2008.11.010, 19070661.
23. Tanaka T, Shiramoto S, Miyashita M, Fujishima Y, Kaneo Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm 2004, 277:39-61. 10.1016/j.ijpharm.2003.09.050, 15158968.
24. Hofmann B, Bogdanov A, Marecos E, Ebert W, Semmler W, Weissleder R. Mechanism of gadophrin-2 accumulation in tumor necrosis. J Magn Reson Imaging 1999, 9:336-341. 10.1002/(SICI)1522-2586(199902)9:2<336::AID-JMRI28>3.0.CO;2-3, 10077034.
25. Becker A, Riefke B, Ebert B, Sukowski U, Rinneberg H, Semmler W, Licha K. Macromolecular contrast agents for optical imaging of tumors: comparison of indotricarbocyanine-labeled human serum albumin and transferrin. Photochem Photobiol 2000, 72:234-241. 10.1562/0031-8655(2000)072<0234:MCAFOI>2.0.CO;2, 10946578.
26. Chen K, Xie J, Chen X. RGD-human serum albumin conjugates as efficient tumor targeting probes. Mol Imaging 2009, 8:65-73.
27. Gross S, Gilead A, Scherz A, Neeman M, Salomon Y. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat Med 2003, 9:1327-1331. 10.1038/nm940, 14502284.
28. Mazor O, Brandis A, Plaks V, Neumark E, Rosenbach-Belkin V, Salomon Y, Scherz A. WST11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake, pharmacokinetics, biodistribution and vascular-targeted photodynamic activity using melanoma tumors as a model. Photochem Photobiol 2005, 81:342-351. 10.1562/2004-06-14-RA-199.1, 15623318.
29. Koudinova NV, Pinthus JH, Brandis A, Brenner O, Bendel P, Ramon J, Eshhar Z, Scherz A, Salomon Y. Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int J Cancer 2003, 104:782-789. 10.1002/ijc.11002, 12640688.
30. Trachtenberg J, Bogaards A, Weersink RA, Haider MA, Evans A, McCluskey SA, Scherz A, Gertner MR, Yue C, Appu S, Aprikian A, Savard J, Wilson BC, Elhilali M. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol 2007, 178:1974-1979. discussion 1979, 10.1016/j.juro.2007.07.036, 17869307.
31. Trachtenberg J, Bogaards A, Weersink RA, Haider MA, Evans A, McCluskey SA, Scherz A, Gertner MR, Yue C, Appu S, Aprikian A, Savard J, Wilson BC, Elhilali M. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int 2008, 102:556-562. 10.1111/j.1464-410X.2008.07753.x, 18494829.
32. Eggener SE, Coleman JA. Focal treatment of prostate cancer with vascular-targeted photodynamic therapy. Scientific World Journal 2008, 8:963-973. 2692990, 18836668.
33. Davidson SR, Weersink RA, Haider MA, Gertner MR, Bogaards A, Giewercer D, Scherz A, Sherar MD, Elhilali M, Chin JL, Trachtenberg J, Wilson BC. Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer. Phys Med Biol 2009, 54:2293-2313. 10.1088/0031-9155/54/8/003, 19305043.
34. Pinthus JH, Bogaards A, Weersink R, Wilson BC, Trachtenberg J. Photodynamic therapy for urological malignancies: past to current approaches. J Urol 2006, 175:1201-1207. 10.1016/S0022-5347(05)00701-9, 16515960.
35. Lepor H. Vascular targeted photodynamic therapy for localized prostate cancer. Rev Urol 2008, 10:254-261. 2615102, 19145269.
36. Meerovich IG, Brandis A, Meerovich GA, Stratonnikov AA, Bendel P, Oborotova NA, Shertz A, Baryshnikov AY. Study of manganese bacteriopheophorbide as a potential contrast agent for magnetic resonance tomography. Bull Exp Biol Med 2007, 143:452-454. 10.1007/s10517-007-0154-3, 18214298.
37. Scherz A, Salomon Y, Rubinstein E, Brandis A, Eren D, Neimann K. Conjugates of RGD peptides and porphyrin and (bacterio) chlorophyll derivatives and their uses. International PCT Patent Application and US Application No 11/843,996 2007,
38. Brandis A, Mazor O, Neumark E, Rosenbach-Belkin V, Salomon Y, Scherz A. Novel water-soluble bacteriochlorophyll derivatives for vascular-targeted photodynamic therapy: synthesis, solubility, phototoxicity and the effect of serum proteins. Photochem Photobiol 2005, 81:983-993. 10.1562/2004-12-01-RA-389R1.1, 15839743.
39. Berdugo M, Bejjani RA, Valamanesh F, Savoldelli M, Jeanny JC, Blanc D, Ficheux H, Scherz A, Salomon Y, BenEzra D, Behar-Cohen F. Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes. Invest Ophthalmol Vis Sci 2008, 49:1633-1644. 10.1167/iovs.07-0767, 18385085.
40. Ashur I, Goldschmidt R, Pinkas I, Salomon Y, Szewczyk G, Sarna T, Scherz A. Photocatalytic generation of oxygen radicals by the water-soluble bacteriochlorophyll derivative WST11, noncovalently bound to serum albumin. J Phys Chem A 2009, 113:8027-8037. 10.1021/jp900580e, 19545111.
41. Takagi J. Structural basis for ligand recognition by RGD (Arg-Gly-Asp)-dependent integrins. Biochem Soc Trans 2004, 32:403-406. 10.1042/BST0320403, 15157147.
42. Temming K, Schiffelers RM, Molema G, Kok RJ. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 2005, 8:381-402. 10.1016/j.drup.2005.10.002, 16309948.
43. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001, 42:326-336.
44. Rubinstein E. Targeted photodynamic drugs: Design, Synthesis and Applications. PhD thesis 2007, Weizmann Institute of Science.
45. Vakrat-Haglili Y, Weiner L, Brumfeld V, Brandis A, Salomon Y, McLlroy B, Wilson BC, Pawlak A, Rozanowska M, Sarna T, Scherz A. The microenvironment effect on the generation of reactive oxygen species by Pd-bacteriopheophorbide. J Am Chem Soc 2005, 127:6487-6497. 10.1021/ja046210j, 15853357.
46. Sorensen AG, Patel S, Harmath C, Bridges S, Synnott J, Sievers A, Yoon YH, Lee EJ, Yang MC, Lewis RF, Harris GJ, Lev M, Schaefer PW, Buchbinder BR, Barest G, Yamada K, Ponzo J, Kwon HY, Gemmete J, Farkas J, Tievsky AL, Ziegler RB, Salhus MR, Weisskoff R. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 2001, 19:551-557.
47. Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R, Noonan DM, Natali PG, Albini A. The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer 2000, 87:336-342. 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3, 10897037.
48. Max R, Gerritsen RR, Nooijen PT, Goodman SL, Sutter A, Keilholz U, Ruiter DJ, De Waal RM. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 1997, 71:320-324. 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.0.CO;2-#, 9139861.
49. Berton G, Lowell CA. Integrin signalling in neutrophils and macrophages. Cell Signal 1999, 11:621-635. 10.1016/S0898-6568(99)00003-0, 10530871.
50. Hendey B, Lawson M, Marcantonio EE, Maxfield FR. Intracellular calcium and calcineurin regulate neutrophil motility on vitronectin through a receptor identified by antibodies to integrins alphav and beta3. Blood 1996, 87:2038-2048.